Subscribe To Our Free Newsletter |
Alembic Pharma slips 5%; board approves Rs 1,150 cr as impairment charges
This one time impairment impact notwithstanding, we believe this move bodes well for future return ratios and profitability. We expect more impairments in due course, ICICI Securities said in a note.